Estimated risks of venous thromboembolism (VTE) in patients exposed to hormonal therapy or pregnancy.*
| . | Baseline relative risk . | 20 year old with thrombophilia; est. events per 10,000 women-yrs** . | 60 year old with thrombophilia; est. events per 10,000 women-yrs** . | ***Risk in Factor V Leiden heterozygote . | ***Risk in Prothrombin 20210 heterozygote . |
|---|---|---|---|---|---|
| *Estimated from available literature. Numbers shown in italics are based on limited data. | |||||
| **Calculated based on incidence of VTE in 20 year old of 1/10,000 and in 60 year old of 10/10,000 | |||||
| *** Risk compared to women without the mutation and not receiving hormonal therapy or pregnant | |||||
| ****Estimate based on combined 2nd and 3rd generation OCP data, but 73% of women enrolled in study were on 3rd generation OCP | |||||
| 2nd generation OCP | 4 | 4 | 20-35 | ||
| 3rd generation OCP | 6 – 8 | 5-6 | 50 | 16**** | |
| Pregnancy | 5 - 6 | ||||
| HRT | 2 - 4 | 20-40 | 13 | ||
| Tamoxifen/Raloxifene | 3 - 7 | 30-70 | |||
| Tamoxifen with adjuvant chemotherapy | 5 - 15 | 50-150 | |||
| . | Baseline relative risk . | 20 year old with thrombophilia; est. events per 10,000 women-yrs** . | 60 year old with thrombophilia; est. events per 10,000 women-yrs** . | ***Risk in Factor V Leiden heterozygote . | ***Risk in Prothrombin 20210 heterozygote . |
|---|---|---|---|---|---|
| *Estimated from available literature. Numbers shown in italics are based on limited data. | |||||
| **Calculated based on incidence of VTE in 20 year old of 1/10,000 and in 60 year old of 10/10,000 | |||||
| *** Risk compared to women without the mutation and not receiving hormonal therapy or pregnant | |||||
| ****Estimate based on combined 2nd and 3rd generation OCP data, but 73% of women enrolled in study were on 3rd generation OCP | |||||
| 2nd generation OCP | 4 | 4 | 20-35 | ||
| 3rd generation OCP | 6 – 8 | 5-6 | 50 | 16**** | |
| Pregnancy | 5 - 6 | ||||
| HRT | 2 - 4 | 20-40 | 13 | ||
| Tamoxifen/Raloxifene | 3 - 7 | 30-70 | |||
| Tamoxifen with adjuvant chemotherapy | 5 - 15 | 50-150 | |||